Trial Profile

A phase 2 Proof-of-Concept study of ABX-002 in treatment of Treatment Resistant Depression (TRD)

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 12 Sep 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ABX-002 (Primary)
Indications Depression
Focus Proof of concept; Therapeutic Use
Sponsors Autobahn Therapeutics

Most Recent Events

12 Sep 2022 New trial record
08 Sep 2022 According to an Autobahn Therapeutics media release, the company has raised 32.7 Million Dollars to supports advancement of ABX-002 through Phase 2 Proof-of-Concept clinical study in Treatment Resistant Depression.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com